These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 18198941)

  • 1. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
    Denton PW; Estes JD; Sun Z; Othieno FA; Wei BL; Wege AK; Powell DA; Payne D; Haase AT; Garcia JV
    PLoS Med; 2008 Jan; 5(1):e16. PubMed ID: 18198941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can the new humanized mouse model give HIV research a boost.
    Shacklett BL
    PLoS Med; 2008 Jan; 5(1):e13. PubMed ID: 18198940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.
    Denton PW; Krisko JF; Powell DA; Mathias M; Kwak YT; Martinez-Torres F; Zou W; Payne DA; Estes JD; Garcia JV
    PLoS One; 2010 Jan; 5(1):e8829. PubMed ID: 20098623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
    Denton PW; Othieno F; Martinez-Torres F; Zou W; Krisko JF; Fleming E; Zein S; Powell DA; Wahl A; Kwak YT; Welch BD; Kay MS; Payne DA; Gallay P; Appella E; Estes JD; Lu M; Garcia JV
    J Virol; 2011 Aug; 85(15):7582-93. PubMed ID: 21593172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI; Uthman OA; Okoromah CA
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007189. PubMed ID: 22786505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
    Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E
    HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
    Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
    J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection.
    Olesen R; Wahl A; Denton PW; Garcia JV
    J Reprod Immunol; 2011 Mar; 88(2):195-203. PubMed ID: 21256601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
    Clercq ED
    Biochem Pharmacol; 2012 Mar; 83(5):567-73. PubMed ID: 22067069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
    Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
    Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
    Moss JA; Srinivasan P; Smith TJ; Butkyavichene I; Lopez G; Brooks AA; Martin A; Dinh CT; Smith JM; Baum MM
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice.
    Li Q; Tso FY; Kang G; Lu W; Li Y; Fan W; Yuan Z; Destache CJ; Wood C
    J Acquir Immune Defic Syndr; 2015 Aug; 69(5):519-27. PubMed ID: 26167617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pre-exposure prophylaxis for HIV transmission? No, unless].
    Boeke AJ; Heijnen AM
    Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
    Expert Rev Clin Immunol; 2010 Mar; 6(2):186. PubMed ID: 20402380
    [No Abstract]   [Full Text] [Related]  

  • 19. Modeling HIV-1 Mucosal Transmission and Prevention in Humanized Mice.
    Veselinovic M; Charlins P; Akkina R
    Methods Mol Biol; 2016; 1354():203-20. PubMed ID: 26714714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.